Search

A recent study conducted in China focused on the treatment and survival outcomes of non-metastatic small cell carcinoma of the bladder (SCCB). The research included 20 patients with localized or locally advanced disease who received various treatments such as chemotherapy, partial cystectomy, and radical cystectomy. The study highlighted the importance of chemotherapy in treating SCCB and showed promising survival outcomes for patients who underwent radical cystectomy or radiotherapy. This study, which reported the largest cohort of non-metastatic SCCB among the Chinese population, provides valuable insights into the management of this rare and highly malignant tumor. [Extracted from the article]

A recent report from the University of California Irvine discusses the role of maximal debulking transurethral resection of bladder tumor (TURBT) in managing non-metastatic muscle-invasive bladder cancer (MIBC) as part of a bladder-preserving approach. While radical cystectomy is the standard treatment for MIBC, bladder-preserving therapies like TURBT and chemoradiation offer alternatives for patients who are not suitable candidates for surgery. However, TURBT carries risks such as bleeding, infection, and bladder perforation, highlighting the need for individualized treatment plans and further research to optimize patient outcomes. [Extracted from the article]

Researchers at the University of Miami have reported new data on metastatic pleomorphic lobular carcinoma of the breast to the urinary bladder, a rare occurrence with similarities to plasmacytoid urothelial carcinoma. The study aimed to distinguish between the two types of cancer using various markers, including TRPS1. Results showed that MPLC often presents in patients with a history of breast cancer and can be differentiated from PUC based on immunohistochemical markers. The researchers caution that misclassification of these tumors can have significant ramifications. [Extracted from the article]

A recent report from Ningbo Urology and Nephrology Hospital discusses the clinical utility of en bloc resection in treating non-muscle invasive bladder cancer. The study highlights the advantages of this surgical technique, such as improved pathological outcomes, reduced complications, and lower recurrence rates. The research reviews the history, surgical steps, indications, and potential benefits of en bloc resection in managing bladder cancer. For more information, readers can access the full article in Discover Oncology. [Extracted from the article]

Researchers at the Cleveland Clinic conducted a study on the impact of pathologic re-review on grade, clinical stage, and risk stratification for patients with nonmuscle invasive bladder cancer. The study found that re-review of transurethral resection of bladder tumor specimens led to changes in disease risk stratification for over one-fifth of patients, potentially affecting their management. The research, published in Urologic Oncology Seminars and Original Investigations, highlights the importance of accurate pathology review in determining treatment strategies for bladder cancer patients. [Extracted from the article]

Research from Policlinico Umberto I Hospital in Rome, Italy, has identified blood extracellular vesicles as a valuable risk stratification biomarker in high-risk non-muscle-invasive bladder cancer patients. The study evaluated the enumeration of tumour-derived extracellular vesicles and circulating tumour cells in these patients, finding that the presence of at least one circulating tumour cell was associated with a shorter time to progression and cancer-specific survival. The researchers concluded that combining tumour-derived extracellular vesicles and circulating tumour cells improves risk stratification for bladder cancer progression, suggesting that extracellular vesicles could be valuable biomarkers for prognosis and disease monitoring. [Extracted from the article]

A recent report from Changhua Christian Hospital discusses a case of primary lymphoma of mucosa-associated lymphoid tissue (MALT) in the urinary bladder, which presented symptoms mimicking recurrent urinary tract infections in a 79-year-old woman. The patient underwent transurethral resection of the bladder tumor, followed by adjuvant radiotherapy, and was successfully treated with no signs of disease at the 9-month follow-up. The research emphasizes the importance of histopathology and immunohistochemistry for a definitive diagnosis of bladder lymphoma, highlighting the need for further research to determine optimal treatment strategies. [Extracted from the article]

A patent has been issued for peptides, a combination of peptides, and cell-based medicaments for use in immunotherapy against urinary bladder cancer and other cancers. Bladder cancer is described in detail, including its types, stages, treatment options, and survival rates. The patent focuses on a peptide sequence and its variants that bind to MHC and induce T cells, potentially offering new avenues for immunotherapy in bladder cancer treatment. [Extracted from the article]

A recent study conducted at Stanford University in California examined the presence and implications of adipose tissue in urinary bladder biopsies and transurethral resection specimens. The study found that adipose tissue was commonly found in these specimens, primarily in the lamina propria and sometimes extending into the muscularis propria. However, the presence of tumor "invading" fat in these specimens does not necessarily indicate advanced disease. The researchers emphasized the need for standardized reporting practices and the importance of reserving pathologic staging for cystectomy specimens. [Extracted from the article]

A recent report discusses research findings on bladder cancer treatment at the Cleveland Clinic in Ohio. The study aimed to evaluate the impact of clinical progression during neoadjuvant chemotherapy (NAC) on eligibility for a vaginal-sparing cystectomy. The researchers retrospectively reviewed 89 female patients with non-metastatic muscle-invasive bladder cancer who underwent NAC and radical cystectomy. The results showed that while clinical upstaging after NAC was infrequent, 5% of patients with trigonal bladder cancer were rendered ineligible for vaginal-sparing cystectomy due to progression. The study suggests that interim imaging assessment may help identify non-responders and preserve eligibility for vaginal-sparing surgery. [Extracted from the article]

A study conducted at University Hospital 12 de Octubre in Madrid, Spain, examined the survival outcomes and palliative care needs of patients diagnosed with muscle-invasive bladder cancer (MIBC) who were not eligible for curative treatment. The study included 142 patients with a median age of 79.4 years. The results showed that patients who were unable or unwilling to undergo curative treatment had a median overall survival of less than one year, with worse outcomes observed in those with advanced disease stage and hydronephrosis. The study also found that patients visited the emergency department multiple times and underwent various palliative procedures. [Extracted from the article]

Non-muscle-invasive bladder cancer (NMIBC) is a type of bladder cancer that remains confined to the innermost lining layer of the bladder without spreading into the muscle. It is a common form of bladder cancer and is usually associated with superficial tumor growth. The current treatment plan for NMIBC involves surgery, intravesical immunotherapy, and intravesical chemotherapy. The FDA has approved three drugs for treating NMIBC: KEYTRUDA, ADSTILADRIN, and ANKTIVA. There are also several other potential therapies in development for NMIBC. The market size for NMIBC is expected to grow significantly in the coming years. [Extracted from the article]

Immatics Biotechnologies GmbH has been granted a patent for peptides and cell-based medicaments that can be used in immunotherapy for urinary bladder cancer and other cancers. The patent explains the different types and stages of bladder cancer, as well as the standard treatments available. The invention focuses on a peptide sequence that can bind to MHC and stimulate T cells that react with the peptide, potentially aiding in the diagnosis and treatment of bladder cancer. The patent also mentions the use of adjuvants and pegylation in the composition of the peptides. This article provides a summary of various topics related to surgery, genetics, oncology, and bladder cancer, presenting research on cystectomy, immunology, lymph nodes, chemotherapy, bone research, immunotherapy, urinary diversion, papillary cancer, drugs and therapies, post-trial research, and risk and prevention. It is a fact-based report that aims to deliver news on research and discoveries from around the world. [Extracted from the article]

A recent report from the Department of Anesthesiology and Intensive Care in Sofia, Bulgaria, highlights the role of spinal anesthesia in improving postoperative oncologic outcomes for non-muscle invasive bladder cancer patients undergoing transurethral resection of the bladder tumor (TURBT). The study found that spinal anesthesia compared to general anesthesia improved outcomes, and the coadministration of opioids did not affect NK cells function and improved postoperative opioid sparing. The research suggests that spinal anesthesia with intrathecal opioid coadministration may play a significant complementary role in improving oncologic outcomes after TURBT for bladder cancer. [Extracted from the article]

A clinical trial, NCT06564363, is being conducted to determine the efficacy of the IUrisure test in detecting recurrent urothelial carcinoma. The trial aims to compare the sensitivity and specificity of the IUrisure test to the gold standard methods of cystoscopy and pathology. The study is currently recruiting patients and is expected to be completed by September 30, 2025. The trial is being conducted by Wuhan Ammunition Life-tech Co., Ltd in China. [Extracted from the article]

The article details a study comparing UGN-102, an intravesical chemoablation therapy, with transurethral resection of bladder tumor (TURBT) alone for treating low-grade intermediate-risk nonmuscle-invasive bladder cancer. Topics discussed include the trial's design, efficacy and safety results, and the adverse events associated with UGN-102.

A patent has been issued for methods of treating tumor metastasis. The patent describes a method of locally delivering a chemotherapeutic agent, such as gemcitabine, to the bladder for a prolonged period of time to treat or suppress tumor metastasis at a site distinct from the bladder. The method has shown an extraordinary antitumor effect and can be used to treat non-bladder tumors as well. The patent also includes definitions and claims related to inducing an immune response against tumor cells. [Extracted from the article]

A recent study conducted at the University of Washington explored the use of neoadjuvant nivolumab-based immunotherapy in patients with muscle-invasive bladder cancer who were ineligible for cisplatin-based chemotherapy. The study found that this treatment approach was safe, feasible, and well-tolerated in these patients. While the pathologic response rates were lower than expected, the survival rates were comparable to other neoadjuvant immunotherapy trials. This research provides valuable insights for patients with muscle-invasive bladder cancer who cannot receive cisplatin-based chemotherapy. [Extracted from the article]

A recent study from Stanford University explores the potential of artificial intelligence (AI) and enhanced imaging techniques in improving the diagnosis and treatment of bladder cancer. The researchers highlight the limitations of current surgical techniques and tools, which contribute to high recurrence and progression rates in bladder cancer. They suggest that advancements in AI and enhanced cystoscopy technologies offer promising solutions to address these challenges and improve tumor delineation and resection. This research has been peer-reviewed and provides valuable insights for the field of urology. [Extracted from the article]

A patent has been issued for a device designed to reduce the risk of complications during electrosurgical interventions. The device is particularly useful for procedures such as transurethral electro-resection of the bladder, transurethral electro-resection of the prostate, and transcervical resection. It includes a generator for creating treatment voltage, an instrument with electrodes, and a sensor attached to the patient to detect movement. The device's control device can quickly recognize muscle contractions caused by neuromuscular stimulation and adjust the generator's operation to prevent undesired patient movements and potential complications. [Extracted from the article]

A new report from the Veneto Institute of Oncology in Padua, Italy presents fresh data on bladder cancer. The researchers aimed to assess the feasibility and diagnostic adequacy of PD-L1 expression analysis using cytoinclusion in bladder cancer patients. They collected urinary and tissue specimens from patients undergoing endoscopic transurethral resection of bladder tumor, repeat TURBT, or robot-assisted radical cystectomy. The study found that cytoinclusion could serve as a minimally invasive method for quantifying urinary PD-L1 percentages, potentially serving as both a prognostic and diagnostic indicator. Standardizing this technique could make it a valuable tool in the future. [Extracted from the article]

A study conducted at the Jawaharlal Institute of Postgraduate Medical Education and Research in Puducherry, India, explored treatment adherence patterns in patients with nonmuscle invasive bladder cancer (NMIBC). The study found that a significant number of patients were nonadherent to follow-up protocols, with inadequate physician explanation being the primary cause of nonadherence. Other factors that impacted adherence included economic constraints and side effects of treatment. The study highlights the need for tailored interventions to improve patient education, communication, and economic support in order to enhance adherence to NMIBC follow-up protocols. [Extracted from the article]

A recent report from the Department of Medicine discusses the importance of accurate staging in bladder cancer (BCa) and explores the potential benefits of incorporating multiparametric magnetic resonance imaging (mpMRI) and the Vesical Imaging Reporting Data System (VI-RADS) into BCa staging. The review found that VI-RADS scoring accurately predicted muscle invasion, aiding in distinguishing non-muscle-invasive bladder cancer (NMIBC) from muscle-invasive bladder cancer (MIBC). VI-RADS potentially identified patients who would benefit from repeat transurethral resection of bladder tumor (re-TURBT) and those for whom it could be safely omitted. However, further research is needed to validate the utility of VI-RADS and refine selection criteria. The integration of VI-RADS into BCa staging holds potential benefits for patients and healthcare systems. [Extracted from the article]

A new report from the University Hospital of Bicetre in Le Kremlin-Bicetre, France, discusses the management of high-grade papillary Ta or T1 bladder cancer after restaging transurethral resection (reTURB). The study compares the recurrence-free survival rates of patients who underwent different management procedures, specifically BCG instillations upfront versus BCG following a third-look resection (3TURB). The research found that patients who received BCG instillations upfront had significantly better recurrence-free survival rates. However, the study could not determine the value of a 3TURB compared to upfront BCG. This research provides valuable insights into the management of high-risk non-muscle invasive bladder cancer. [Extracted from the article]

A recent report from Sun Yat-sen University Cancer Center in Guangzhou, China, discusses the use of cryoablation therapy as a potential treatment for bladder cancer. Bladder cancer is categorized into urothelial and non-urothelial types, with urothelial carcinoma being the most common. The standard treatment for non-muscle-invasive bladder cancer is transurethral resection of bladder tumors, while neoadjuvant chemotherapy followed by radical cystectomy is the standard for muscle-invasive bladder cancer. Cryoablation therapy, which uses extremely low temperatures to destroy diseased tissue, has emerged as a minimally invasive and precise treatment option for early bladder cancer. However, more randomized controlled trials are needed to determine patient selection criteria and treatment approaches. [Extracted from the article]

A patent has been issued for methods of treatment and maintenance therapy for bladder cancer using gemcitabine. Bladder cancer is classified as muscle invasive bladder cancer (MIBC) or non-muscle invasive bladder cancer (NMIBC), and current treatment options are unsatisfactory. The patent describes methods of administering gemcitabine locally to the bladder of an individual during induction and maintenance phases, with rest periods in between. The gemcitabine can be delivered using an intravesicular device, and the maintenance therapy can continue for at least one year. This patent provides potential treatment options for individuals with bladder cancer who are not eligible for or have refused other treatments. [Extracted from the article]

A case report from Shanghai Jiao Tong University School of Medicine discusses the occurrence of non-bacterial cystitis in a 27-year-old female patient with adenocarcinoma of the lung who was undergoing pembrolizumab-combined chemotherapy treatment. The patient experienced urinary irritation symptoms, and further examination revealed inflammation in the bladder mucosal layer. The researchers concluded that this was a case of non-bacterial inflammation of the urinary tract caused by immunotherapy. Immune checkpoint inhibitors, such as pembrolizumab, have shown extended survival benefits for lung cancer patients but can also lead to immune-related adverse events. [Extracted from the article]

A report from Kochi University School of Medicine in Japan discusses the distinct molecular profiles of bladder cancer and how they influence progression and treatment outcomes. The standard treatment for non-muscle-invasive bladder cancer (NMIBC) is transurethral resection of bladder tumor (TURBT), which serves both diagnostic and therapeutic purposes. The report highlights the use of a new-generation photosensitizer called 5-Aminolevulinic acid (5-ALA) for photodynamic diagnosis and therapy in NMIBC. The researchers suggest that 5-ALA may contribute to screening before and after TURBT, potentially improving patient outcomes. [Extracted from the article]

This document provides information about a clinical trial, NCT06474338, that aims to determine if an artificial intelligence (AI) algorithm can detect bladder tumors more effectively than urologists during cystoscopy. The trial will train the AI algorithm for bladder tumor detection and compare its performance to that of urologists. Cystoscopy videos will be annotated by both AI and urologists, and the AI algorithm will be evaluated based on various metrics. The trial seeks to address the diagnostic deficiencies of white light cystoscopy in detecting bladder cancer. The study is currently recruiting participants in China and is expected to be completed by December 31, 2033. [Extracted from the article]

A study conducted at the University of Pittsburgh discusses the case of an 81-year-old man from South Korea who was referred to a pulmonology clinic due to abnormal findings on a routine surveillance CT scan. The patient had a history of various medical conditions, including tuberculous pleurisy in his third decade of life. He was later diagnosed with active tuberculosis and underwent treatment. However, a subsequent surveillance CT scan revealed interval growth of a thoracic lesion, leading to further evaluation and confirmation of a diagnosis of pyothorax-associated lymphoma. The study emphasizes the importance of repeat biopsies and appropriate treatment based on imaging findings. [Extracted from the article]

A recent study conducted at Sichuan University in China compared the efficiency of two surgical methods for treating non-muscle-invasive bladder cancer (NMIBC). The study found that en-bloc transurethral resection of bladder tumor (ERBT) was associated with a lower rate of bladder perforation and obturator nerve reflex compared to conventional transurethral resection of bladder tumor (cTURBT). ERBT also showed superior performance in terms of detrusor muscle presence, catheterization time, residual tumor, and recurrence-free survival. The researchers concluded that ERBT may be a better surgical method for NMIBC patients compared to cTURBT. [Extracted from the article]

A recent study conducted by researchers at Indiana University School of Medicine examined the impact of variant histology (VH) on the upstaging and survival of patients with nonmuscle invasive bladder cancer (NMIBC) undergoing radical cystectomy (RC). The study found that patients with VH NMIBC had a significantly higher rate of upstaging at RC compared to patients with pure urothelial NMIBC. Additionally, patients with VH NMIBC had worse overall survival compared to those with pure urothelial NMIBC. The study supports the idea of an aggressive treatment approach for patients with VH NMIBC, but further research is needed to improve outcomes. [Extracted from the article]

A recent study conducted by researchers at George Washington University examined the efficacy of cytoreductive radical cystectomy (CRC) in metastatic urothelial bladder cancer (mBCa). The study analyzed data from patients treated with multiagent chemotherapy between 2004 and 2019 and classified them based on whether they received CRC or conservative local treatment (CLT). The results showed that CRC was associated with a greater overall survival (OS) compared to CLT, particularly in patients with distant lymph node metastasis, any organ metastasis, and single visceral metastasis. However, CRC did not significantly improve OS in patients with multiple metastases. These findings suggest that CRC may be beneficial in certain cases of mBCa and highlight the importance of further research in this area. [Extracted from the article]

A recent study conducted at the Fox Chase Cancer Center in Philadelphia, Pennsylvania aimed to describe the symptoms and functional recovery experienced by patients after transurethral resection of bladder tumors. The study found that postoperative symptoms were generally mild and recovery was rapid, with 76% of patients reporting feeling recovered by postoperative day 2. However, a small number of patients experienced longer recoveries. The study also found that receiving perioperative intravesical chemotherapy was associated with a longer time to recovery. Overall, the negative effects on quality of life resulting from the procedure were generally mild and short-lived. [Extracted from the article]

Photocure ASA has launched a new initiative to increase access to blue light cystoscopy (BLC) for hospitals and clinics in the U.S. The initiative involves a mobile capital equipment model, which eliminates the need for capital budget approvals and allows hospitals to use operating budgets instead. This will enable physicians and patients to benefit from BLC with Cysview. ForTec Medical, in collaboration with Karl Storz and Photocure, will provide the mobile equipment and support services. The program is expected to expand nationally throughout the year, improving access to quality bladder cancer care. [Extracted from the article]

A study conducted in Brazil aimed to evaluate the impact of a shortage of bacillus Calmette-Guerin (BCG) on the recurrence and progression of non-muscle invasive bladder cancer. The researchers retrospectively reviewed the data of 409 patients who underwent transurethral resection of the bladder tumor between June 2014 and May 2021. The study found that the use of adjuvant BCG significantly reduced the recurrence rate in intermediate and high-risk patients. However, the shortage of BCG may have negatively impacted these patients. [Extracted from the article]

The Third Affiliated Hospital, Sun Yat-Sen University in China is conducting a clinical trial, NCT06442839, to develop a CT-based tumor budding predictive model for bladder cancer using deep learning algorithms. The trial aims to improve the preoperative assessment of bladder cancer patients and create more precise and personalized treatment plans. The study will recruit 2000 participants and is expected to be completed by December 2024. Eligible participants must have undergone transurethral resection of bladder tumor or radical cystectomy and have complete clinical, preoperative CT, and pathological data. The model's performance will be evaluated using external validation cohorts from different hospitals. [Extracted from the article]

A recent study conducted at the Cleveland Clinic in Ohio examined the oncologic outcomes of intravesical therapy in the management of nonmuscle invasive bladder cancer (NMIBC) with variant histology (VH). The study found that bladder-sparing treatment with intravesical therapy demonstrated acceptable oncologic outcomes for most VHs, making it a potential treatment option for patients who are not suitable candidates for cystectomy or who prioritize bladder-sparing treatment. However, patients with certain VH subgroups, such as sarcomatoid, plasmacytoid, and micropapillary, had significantly worse outcomes. The study highlights the need for further research and personalized treatment approaches for NMIBC with VH. [Extracted from the article]

A study conducted in Anhui, People's Republic of China, investigated the efficacy of sequential gemcitabine and epirubicin therapy on high-risk non-muscle invasive bladder cancer (NMIBC) after transurethral resection of bladder tumor (TURBT). The study analyzed the records of 100 high-risk NMIBC patients who underwent TURBT at Tongling People's Hospital. The results showed that sequential therapy with gemcitabine and epirubicin was effective in treating high-risk NMIBC after TURBT, reducing postoperative recurrence rates and improving postoperative quality of life without increasing adverse reactions. However, further analysis is needed for improved outcomes. [Extracted from the article]

Ractigen Therapeutics has received Fast Track Designation (FTD) from the U.S. Food and Drug Administration (FDA) for its saRNA therapy, RAG-01. This marks a significant milestone in the development of saRNA technology and highlights Ractigen's commitment to addressing unmet medical needs. RAG-01 is currently undergoing a Phase I clinical trial in Australia for the treatment of non-muscle invasive bladder cancer (NMIBC). The FDA's approval of the Investigational New Drug (IND) application for RAG-01 allows for the expansion of clinical trials in the United States and demonstrates the FDA's recognition of its potential in addressing the urgent medical needs of NMIBC patients. Fast Track Designation facilitates the expedited development and review process for investigational drugs intended for serious conditions with unmet medical needs. Ractigen's CEO expressed enthusiasm about the FDA's decision and the company's dedication to advancing innovative saRNA therapies. RAG-01 is a saRNA candidate that targets and activates the tumor suppressor gene p21, which has shown significant tumor suppression in mouse models. NMIBC represents a significant unmet need in bladder cancer therapy, and RAG-01's development is a step towards addressing this. RNAa is a clinically validated platform technology that uses saRNA to activate gene expression and restore therapeutic protein levels. Ractigen Therapeutics is a leader in saRNA drug development, utilizing the RNAa mechanism to up-regulate gene expression and treat [Extracted from the article]

A study conducted by researchers at the Medical University of Warsaw in Poland evaluated the accuracy of existing risk stratification models for predicting high-grade recurrence and progression in non-muscle-invasive bladder cancer (NMIBC) patients treated with Bacillus Calmette-Guerin (BCG) therapy. The study found that the currently available risk models, including EORTC, CUETO, and EAU2021, lacked accuracy in predicting high-grade recurrence-free survival (RFS) and progression-free survival (PFS) in NMIBC patients. The researchers identified additional risk factors, such as T1HG at repeat TURBT, tumor multiplicity, previous history of high-grade NMIBC, and EORTC2006 progression risk score, as independent predictors for high-grade RFS. Overall, the study suggests that further research is needed to improve the accuracy of risk stratification models for NMIBC patients. [Extracted from the article]

A study conducted at the Medical University of Vienna in Austria examined the impact of adjuvant therapy on patients with intermediate-risk non-muscle-invasive bladder cancer (NMIBC). The study included 2,206 patients who underwent transurethral resection of bladder tumor for Ta disease. The results showed that adjuvant therapy, such as bacille Calmette-Guerin or chemotherapeutic agents, was associated with better recurrence-free survival (RFS) rates. However, in patients without risk factors, adjuvant intravesical therapy did not result in a clear reduction in the recurrence rate. This research provides valuable insights for the treatment of bladder cancer. [Extracted from the article]

A study conducted at Taichung Veterans General Hospital in Taiwan compared the clinical efficacy of two different strains of Bacillus Calmette-Guerin (BCG) in patients with T1 high grade bladder cancer. The study found that there was no significant difference in recurrence, progression, or side effects between the two BCG strains. Both the Connaught and TICE strains demonstrated comparable three-year recurrence-free survival rates and three-year progression-free survival rates. The researchers concluded that further strain comparisons are necessary due to the global shortage of BCG. [Extracted from the article]

A recent study conducted at Ewha Womans University in Seoul, South Korea explored the impact of different subtypes of bladder cancer on the response to neoadjuvant chemotherapy (NAC) and the evaluation of response using pelvic diffusion-weighted magnetic resonance imaging (DW-MRI). The study found that there was a significant discrepancy between the MRI findings and the radical cystectomy (RC) findings, with 68.3% of cases showing concordance and 31.7% showing discordance. The plasmacytoid subtype of bladder cancer showed the largest discrepancy between MRI and RC findings. The researchers concluded that an accurate pathological diagnosis is crucial for proper treatment of bladder cancer. [Extracted from the article]

A study conducted at the University of Chicago examined the efficacy and toxicity of trimodality therapy using single-agent concurrent capecitabine for patients with muscle-invasive bladder cancer who were not suitable candidates for radical cystectomy or standard chemoradiotherapy. The study included 27 patients who received capecitabine along with radiotherapy after transurethral resection of bladder tumor. The results showed a high rate of bladder control and low rates of acute and late toxicity. This research provides valuable insights into bladder-preserving therapy for patients with bladder cancer. [Extracted from the article]

A recent study conducted at Brugmann University Hospital in Brussels, Belgium, has reported on the case of a 65-year-old man who developed prostato-epididymitis after receiving Bacillus Calmette-Guerin (BCG) therapy for non-invasive urothelial cancer. BCG is commonly used as a therapy for superficial urothelial cancer and is generally well tolerated, but side effects can occur. The patient's symptoms were resolved with treatment, and it was found that the BCG therapy had led to an infection with Mycobacterium tuberculosis complex strain BCG. The study highlights the importance of considering risk factors and potential complications when administering BCG therapy for urothelial cancer. [Extracted from the article]

A recent report discusses research on bladder cancer and the search for noninvasive biomarkers in body fluids such as blood and urine. The researchers focused on extracellular vesicles (EVs), which contain small noncoding RNA, including transfer RNA-derived fragments (tRFs) and microRNA. They performed small-RNA next-generation sequencing on EVs from urine and serum samples collected from non-cancer patients and patients with non-muscle invasive bladder cancer. The study identified several tRFs that may have potential as biomarkers for the diagnosis and recurrence-free survival of bladder cancer. [Extracted from the article]